Bionano GenomicsBNGO
BNGO
About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.
Employees: 344
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
342% more call options, than puts
Call options by funds: $106K | Put options by funds: $24K
3.23% less ownership
Funds ownership: 9.61% [Q2] → 6.38% (-3.23%) [Q3]
10% less funds holding
Funds holding: 58 [Q2] → 52 (-6) [Q3]
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
45% less capital invested
Capital invested by funds: $4.5M [Q2] → $2.48M (-$2.02M) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for BNGO.
Financial journalist opinion
Based on 4 articles about BNGO published over the past 30 days
Neutral
GlobeNewsWire
2 weeks ago
Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant. The Warrants have an exercise price of $0.252 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”).
Neutral
GlobeNewsWire
2 weeks ago
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale of an aggregate of 39,682,540 shares of its common stock (or common stock equivalents) and warrants to purchase up to an aggregate of 39,682,540 shares of common stock (the “Warrants”), at a combined offering price of $0.252 per share of common stock (or per common stock equivalent) and accompanying Warrant in a registered direct offering priced at-the-market under Nasdaq rules. The Warrants will have an exercise price of $0.252 per share, will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”) for a period of five years thereafter.
Neutral
GlobeNewsWire
2 weeks ago
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
SAN DIEGO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has entered into a settlement agreement and amendment to its outstanding senior secured convertible debentures due May 26, 2024 (the “Amendment”). Importantly the Amendment defers the Company's December 2024 amortization payment and reduces the payments due in January 2025 through July 2025 from $1,000,000 per month to $500,000 per month.
Neutral
GlobeNewsWire
4 weeks ago
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Modern Pathology by a group of researchers at the Johns Hopkins University School of Medicine, showing that optical genome mapping (OGM) can outperform traditional techniques in analysis of bone and soft tissue tumors. Several prior publications have shown the utility of OGM compared to traditional cytogenetics in studies of hematologic malignancies, however, data on the application of OGM in solid tumors has been relatively sparse. This study provides compelling support for extending the utility of OGM in cancer beyond hematologic malignancies to solid tumors.
Neutral
Seeking Alpha
2 months ago
Bionano Genomics, Inc. (BNGO) Q3 2024 Earnings Call Transcript
Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes - IR Erik Holmlin - CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam - Scotiabank Destiny Hance - Ladenburg Thalmann Mark Massaro - BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today's conference is being recorded.
Neutral
GlobeNewsWire
2 months ago
Bionano Reports Third Quarter 2024 Results and Highlights Recent Business Progress
Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued clinical service products. Q3 2024 revenue represents a 35% decrease from Q3 2023 Total installed base of 368 optical genome mapping (OGM) systems as of Q3 2024, which represents a 22% increase over Q3 2023 Sold 7,835 nanochannel array flowcells in Q3 2024, which represents a 27% increase from the number of flowcells sold in Q3 2023 Conference call today, November 13, 2024 at 4:30 PM ET SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2024.
Neutral
GlobeNewsWire
2 months ago
Optical Genome Mapping Market to Witness 26.76% CAGR During 2024-2030 - Consumables and Reagents to Register High Growth - Bionano Genomics, Nucleome Informatics, and Praxis Genomics Dominate the Industry
Dublin, Nov. 04, 2024 (GLOBE NEWSWIRE) -- The "Optical Genome Mapping Market Size, Share & Trends Analysis, 2024-2030" report has been added to ResearchAndMarkets.com's offering. The global optical genome mapping market is estimated to reach USD 536.4 million by 2030. The market is projected to grow at a CAGR of 26.76% from 2024 to 2030. This can be attributed to developments in studying efficient treatments for a variety of chronic diseases. The ability of optical genome mapping (OGM) to complement other genomic sequencing technologies, such as next-generation sequencing (NGS), has created synergies in genomics research.
Neutral
GlobeNewsWire
2 months ago
Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the purchase and sale of an aggregate of 9,881,113 shares of its common stock and Series C warrants to purchase up to an aggregate of 9,881,113 shares of common stock and short-term Series D warrants to purchase up to an aggregate of 9,881,113 shares of common stock (collectively, the “Warrants”) at a combined offering price of $0.3039 per share of common stock and accompanying Warrants. The Warrants have an exercise price of $0.3039 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the Warrants (the “Stockholder Approval”). The Series C warrants expire five years following the date of the Stockholder Approval and the short-term Series D warrants expire eighteen months following the date of Stockholder Approval.
Neutral
GlobeNewsWire
2 months ago
Bionano Adjourns Special Meeting of Stockholders to November 27, 2024
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it adjourned its reconvened Special Meeting of Stockholders originally held on October 2, 2024 and subsequently adjourned to October 30, 2024 (the “Special Meeting”) because a quorum was not present at the time of the reconvened meeting. Based on preliminary reports as of October 30, 2024, approximately 30.7% of total shares outstanding as of the record date have submitted their votes, whereas 33.3% of total shares outstanding as of the record date are necessary to satisfy the quorum requirements for a meeting.
Neutral
GlobeNewsWire
3 months ago
Bionano Announces Preliminary 3Q 2024 Revenues and Cash
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced select preliminary results for the quarter ended September 30, 2024. The Company now expects revenue for the third quarter of 2024 to be between $6.5 and $6.8 million, down from prior guidance of between $7.9 and $8.9 million.
Charts implemented using Lightweight Charts™